Varicella zoster (VZ) virus causes two diseases, varicella and zoster. Varicella, primary infection, occurs when individuals lacking immunity to the virus are exposed. Following varicella, many individuals harbor latent VZ virus. Zoster, secondary infection, results from reactivation of latent VZ virus. Most VZ infections are mild in normal hosts. Immunocompromised patients, however, not only often develop severe VZ infections, but they have an increased incidence of zoster in comparison to the normal population.
The aim of this project is to determine why immunocompromised patients tend to develop severe VZ infections and why they are at high risk to manifest reactivation infections due to VZ virus. These studies should provide useful clinical information concerning VZ virus, and they may also contribute significant information concerning viral latency. Humoral and cell mediated immune (CMI) responses to VZ virus will be studied and compared in normal and immunocompromised individuals. Humoral immunity will be measured by sensitive methods, to try to document subclinical as well as clinical reactivation of VZ virus. Shedding of VZ virus by asymptomatic individuals will be looked for. The major thrust of this project, however, will involve of CMI to VZ virus. CMI will be examined by several techniques including T cell and macrophage cytotoxicity, nautral killer cells, antibody dependent cellular cytotoxicity, and lymphocyte transformation. Impaired VZ CMI responses in immunocompromised persons will be correlated with studies of VZ antibody, virus shedding, and development of clinical zoster, to try to identify factors responsible for development of zoster and poor recovery from VZ infections.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Experimental Virology Study Section (EVR)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University (N.Y.)
Schools of Medicine
New York
United States
Zip Code
Fukuyo, Yayoi; Horikoshi, Nobuo; Ishov, Alexander M et al. (2011) The herpes simplex virus immediate-early ubiquitin ligase ICP0 induces degradation of the ICP0 repressor protein E2FBP1. J Virol 85:3356-66
Walters, Matthew S; Kyratsous, Christos A; Silverstein, Saul J (2010) The RING finger domain of Varicella-Zoster virus ORF61p has E3 ubiquitin ligase activity that is essential for efficient autoubiquitination and dispersion of Sp100-containing nuclear bodies. J Virol 84:6861-5
Son, Moeun; Shapiro, Eugene D; LaRussa, Philip et al. (2010) Effectiveness of varicella vaccine in children infected with HIV. J Infect Dis 201:1806-10
Mueller, Niklaus H; Walters, Matthew S; Marcus, Roland A et al. (2010) Identification of phosphorylated residues on varicella-zoster virus immediate-early protein ORF63. J Gen Virol 91:1133-7
Gershon, Anne A; Gershon, Michael D (2010) Perspectives on vaccines against varicella-zoster virus infections. Curr Top Microbiol Immunol 342:359-72
Walters, Matthew S; Kinchington, Paul R; Banfield, Bruce W et al. (2010) Hyperphosphorylation of histone deacetylase 2 by alphaherpesvirus US3 kinases. J Virol 84:9666-76
Gershon, Michael D; Gershon, Anne A (2010) VZV infection of keratinocytes: production of cell-free infectious virions in vivo. Curr Top Microbiol Immunol 342:173-88
Kyratsous, Christos A; Silverstein, Saul J; DeLong, Christine R et al. (2009) Chaperone-fusion expression plasmid vectors for improved solubility of recombinant proteins in Escherichia coli. Gene 440:9-15
Kyratsous, Christos A; Silverstein, Saul J (2009) Components of nuclear domain 10 bodies regulate varicella-zoster virus replication. J Virol 83:4262-74
Walters, Matthew S; Erazo, Angela; Kinchington, Paul R et al. (2009) Histone deacetylases 1 and 2 are phosphorylated at novel sites during varicella-zoster virus infection. J Virol 83:11502-13

Showing the most recent 10 out of 15 publications